Please read and agree to the terms and conditions of this site.
@venturebeat.com 5 years ago
Cytox Launches Collaboration Agreement with Mayo Clinic to Evaluate Novel Genetic Based Approaches for Assessing Alzheimer’s Risk
@venturebeat.com 5 years ago
Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Risk to Include Saliva Samples
@venturebeat.com 6 years ago
‘Citizen AI’: Teaching artificial intelligence to act responsibly
@venturebeat.com 6 years ago
Augmenix to Present at the 36th Annual J.P. Morgan Healthcare Conference
@venturebeat.com 6 years ago
Clew Medical is using AI to identify patients at risk
@venturebeat.com 6 years ago
Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018
@venturebeat.com 6 years ago
Augmenix Partners with Us TOO International to Stream Live Webcast and Q & A on Prostate Cancer Radiation Therapy
@venturebeat.com 6 years ago
Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy of SpaceOAR
@venturebeat.com 6 years ago
Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology
@venturebeat.com 6 years ago
NICE Announces Interventional Procedure Guidance Supporting Use of Hydrogel Spacer in Treatment of Prostate Cancer in the UK
@venturebeat.com 6 years ago
Augmenix, Inc. Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR® Hydrogel
@venturebeat.com 6 years ago
Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year
@venturebeat.com 6 years ago
Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel
@venturebeat.com 6 years ago
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand
@venturebeat.com 6 years ago
SpaceOAR® System Receives Shonin Approval in Japan
@venturebeat.com 6 years ago
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada
@venturebeat.com 7 years ago
Alphabet’s life sciences division Verily launches study to track health data
@venturebeat.com 7 years ago
Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment
@venturebeat.com 7 years ago
Augmenix Announces Positive Three-Year Long-Term Data Highlighting Benefits of SpaceOAR® Hydrogel Spacer for Patients with Prostate Cancer
@venturebeat.com 7 years ago
Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference
@venturebeat.com 7 years ago
Augmenix to Present at the Annual Piper Jaffray Healthcare Conference on Wednesday, November 30
@venturebeat.com 7 years ago
Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material
@venturebeat.com 9 years ago
FDA releases guidance on regulation of ‘wellness’ med devices and accessories
@venturebeat.com 9 years ago
Proteus Digital Health takes in another $52M for meds-monitoring system